Related Experiment Video
Updated: May 6, 2026
06:54
A Model for Encephalomyosynangiosis Treatment after Middle Cerebral Artery Occlusion-Induced Stroke in Mice
Published on: June 22, 2022
2.5K
Paraoxonase 1 in neurological disorders
Redox Report : Communications in Free Radical Research
|November 15, 2013
Summary
Paraoxonase 1 (PON1) influences neurological disorder risk, particularly stroke. Reduced PON1 activity and specific genetic variations are linked to increased stroke and Parkinson's disease risk, especially with organophosphate exposure.
Area of Science:
- Neuroscience
- Biochemistry
- Genetics
Background:
- Paraoxonase 1 (PON1) possesses diverse physiological functions relevant to neurological health.
- Reduced PON1 activity is observed in stroke patients and linked to atherosclerosis.
- PON1's role in detoxifying organophosphates connects it to neurological disorders.
Purpose of the Study:
- To review the literature on paraoxonase 1 (PON1) in the context of stroke and major neurodegenerative diseases.
- To explore the association between PON1 activity, polymorphisms, and the risk of neurological disorders.
- To evaluate the potential pathogenic role and prognostic value of PON1 in neurological conditions.
Main Methods:
- Literature review of studies investigating PON1 in stroke, Parkinson's disease, Alzheimer's disease, multiple sclerosis, and amyotrophic lateral sclerosis.
- Analysis of associations between PON1 activity levels and disease risk.
- Examination of the impact of PON1 genetic polymorphisms (Q192R, L55M) on disease pathogenesis.
Main Results:
- Lower PON1 activity correlates with increased stroke risk and atherosclerosis; the Q192R polymorphism may potentiate this risk.
- PON1's peroxidase activity is relevant to oxidative stress in neurodegeneration.
- While PON1 polymorphisms are not strongly linked to Parkinson's or Alzheimer's, reduced activity suggests a protective role in dementia.
Conclusions:
- Paraoxonase 1 (PON1) is implicated in the pathogenesis of several neurological disorders, including stroke and potentially Parkinson's disease.
- Reduced PON1 activity may indicate a higher risk for certain neurological conditions, suggesting a protective function.
- Further research is needed to clarify PON1's precise role and prognostic significance in neurological diseases.
Related Concept Videos
01:24Parkinson Disease ll: Pathophysiology
34
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
34
01:23Alzheimer Disease ll: Pathophysiology
42
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
42
01:15Parkinson's Disease: Overview
2.2K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.2K
01:37Neural Regulation
34.8K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
34.8K
01:27Protein Import into the Peroxisomes
4.4K
Cells contain membrane-bound organelles called peroxisomes that oxidize organic molecules by transferring hydrogen atoms to oxygen, producing hydrogen peroxide. Peroxisomes enzymatically convert the released hydrogen peroxide into water and oxygen.
Peroxisomal Protein Import:
Peroxisomes lack the genetic machinery required to code for their own proteins. Hence, most peroxisomal membrane, lumenal and transmembrane proteins are synthesized in the cytoplasm or ER and transported to the peroxisome...
Peroxisomal Protein Import:
Peroxisomes lack the genetic machinery required to code for their own proteins. Hence, most peroxisomal membrane, lumenal and transmembrane proteins are synthesized in the cytoplasm or ER and transported to the peroxisome...
4.4K
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
1.2K
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.2K